Siemens Fonds Invest GmbH Has $241,000 Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Siemens Fonds Invest GmbH lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 78.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 563 shares of the company's stock after selling 2,103 shares during the quarter. Siemens Fonds Invest GmbH's holdings in IDEXX Laboratories were worth $241,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. United Capital Financial Advisors LLC raised its stake in IDEXX Laboratories by 0.9% in the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after acquiring an additional 22 shares during the period. Gabelli Funds LLC raised its stake in IDEXX Laboratories by 5.3% in the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after acquiring an additional 25 shares during the period. Perigon Wealth Management LLC raised its stake in IDEXX Laboratories by 1.8% in the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after acquiring an additional 26 shares during the period. Summit Trail Advisors LLC raised its stake in IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after acquiring an additional 26 shares during the period. Finally, Forum Financial Management LP raised its stake in IDEXX Laboratories by 4.9% in the 4th quarter. Forum Financial Management LP now owns 621 shares of the company's stock valued at $257,000 after acquiring an additional 29 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on IDXX. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. Barclays increased their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research note on Tuesday, February 4th. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Wall Street Zen cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Friday. Finally, Stifel Nicolaus increased their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research note on Monday, May 19th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $536.00.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director now directly owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Performance

IDXX stock traded up $11.03 during trading hours on Tuesday, hitting $525.83. 608,785 shares of the stock were exchanged, compared to its average volume of 652,536. The firm has a market capitalization of $42.29 billion, a P/E ratio of 49.28, a P/E/G ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $530.60. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a 50-day simple moving average of $453.81 and a two-hundred day simple moving average of $438.68.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. IDEXX Laboratories's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.71 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.